Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.
A meeting was held at NIBSC, UK in July 2007 to discuss the implications of progress in the use of cell culture systems for the manufacture of vaccines against influenza. Issues discussed included the effect of using eggs and different cell types in strain selection, development of seed viruses to be used in production and the nature of the reagents to be used in determining vaccine potency. Future studies to progress the field were reviewed.
Minor
Philip D
PD
National Institute for Biological Standards and Control, South Mimms, Potters Bar, Herts, UK. pminor@nibsc.ac.uk
Engelhardt
Othmar G
OG
Wood
John M
JM
Robertson
James S
JS
Blayer
Simone
S
Colegate
Tony
T
Fabry
Luc
L
Heldens
Jacco G M
JG
Kino
Yoichiro
Y
Kistner
Otfried
O
Kompier
Ronald
R
Makizumi
Keiichi
K
Medema
Jeroen
J
Mimori
Shigetaka
S
Ryan
David
D
Schwartz
Richard
R
Smith
Jonathan S B
JS
Sugawara
Keishin
K
Trusheim
Heidi
H
Tsai
Theodore F
TF
Krause
Ryoko
R
D017277:Drug Approval; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology*; D009975:Orthomyxoviridae / Q000235:genetics / Q000254:growth & development* / Q000276:immunology*; D016865:Reassortant Viruses / Q000235:genetics / Q000254:growth & development* / Q000276:immunology*; D006113:United Kingdom; D014776:Virus Cultivation / Q000379:methods
D007252:Influenza Vaccines